Dheeraj A. Shinde

Bellinzona, TI, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Artificial intelligence and transforming cancer care.

Artificial intelligence and transforming cancer care.

Journal: Discover oncology
Published: December 25, 2025

Integrated control of cancer stemness by σ1 receptor in advanced prostate cancer.

Integrated control of cancer stemness by σ1 receptor in advanced prostate cancer.

Journal: Oncogene
Published: September 03, 2024

Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer.

Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer.

Journal: Nature communications
Published: April 11, 2023

Metabolomics in oncology.

Metabolomics in oncology.

Journal: Cancer reports (Hoboken, N.J.)
Published: November 16, 2022

Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma.

Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma.

Journal: Cancers
Published: September 21, 2021

Targeting neovascularization and respiration of tumor grafts grown on chick embryo chorioallantoic membranes.

Targeting neovascularization and respiration of tumor grafts grown on chick embryo chorioallantoic membranes.

Journal: PloS one
Published: January 29, 2021

EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.

EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.

Journal: Nature communications
Published: October 27, 2020

Erratum: Mapelli, S.N., et al. A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors). Cancers 2020, 12, 176.

Erratum: Mapelli, S.N., et al. A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors). Cancers 2020, 12, 176.

Journal: Cancers
Published: September 24, 2020

Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer.

Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer.

Journal: Communications biology
Published: July 22, 2020

A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors).

A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors).

Journal: Cancers
Published: December 10, 2019

Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells.

Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells.

Journal: Frontiers in oncology
Published: January 23, 2019

Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer.

Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer.

Journal: European urology oncology
Published: November 20, 2018
Showing 1-12 of 15

Last Updated: 09/26/2026